Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hyperlipidemia is a suspected risk factor for aortic valve stenosis.
• Previous studies on lipid-lowering therapies for aortic stenosis have yielded inconsistent results.

Purpose of the Study:

• To investigate the efficacy of simvastatin plus ezetimibe in patients with mild-to-moderate asymptomatic aortic stenosis.
• To assess the impact of lipid-lowering therapy on cardiovascular events and aortic valve stenosis progression.

Main Methods:

• A randomized, double-blind trial involving 1873 patients.
• Participants received either simvastatin (40 mg) plus ezetimibe (10 mg) or a placebo daily.
• Primary outcome: composite of major cardiovascular events; Secondary outcomes: aortic-valve stenosis events and ischemic cardiovascular events.

Main Results:

• No significant difference in the primary composite outcome between the simvastatin-ezetimibe group and placebo (35.3% vs. 38.2%).
• Aortic-valve replacement rates were similar in both groups (28.3% vs. 29.9%).
• Ischemic cardiovascular events were reduced in the simvastatin-ezetimibe group (hazard ratio, 0.78; P=0.02), primarily due to fewer coronary artery bypass grafting procedures. Cancer incidence was higher in the treatment group (105 vs. 70).

Conclusions:

• Simvastatin and ezetimibe combination therapy did not reduce the composite outcome of aortic valve and ischemic events in patients with aortic stenosis.
• The therapy effectively reduced ischemic cardiovascular events but did not impact aortic-valve stenosis-related events.
• Increased cancer incidence was observed with simvastatin-ezetimibe treatment.